|Bid||62.30 x 300|
|Ask||63.18 x 100|
|Day's Range||62.85 - 63.24|
|52 Week Range||57.18 - 66.80|
|PE Ratio (TTM)||40.11|
|Dividend & Yield||1.88 (3.01%)|
|1y Target Est||N/A|
Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.
In 2016, Merck’s (MRK) Isentress reported revenues of ~$1.4 billion, which reflected an ~8% decline year-over-year.
In 2016, Merck’s Janumet (sitagliptin and metformin HCl) reported revenues of around $2.2 billion, which reflected ~2% YoY growth.